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In Vivo MR Imaging of Magnetically
Labeled Mesenchymal Stem Cells in a Rat
Model of Renal Ischemia
Objective: This study was designed to evaluate in vivo MR imaging for the
depiction of intraarterially injected superparamagnetic iron oxide (SPIO)-labeled
mesenchymal stem cells (MSCs) in an experimental rat model of renal ischemia.
Materials and Methods: Left renal ischemia was induced in 12 male Sprague-
Dawley rats by use of the catheter lodging method. In vivo MR signal intensity
variations depicted on T2*-weighted sequences were evaluated in both the left
and right kidneys prior to injection (n = 2), two hours (n = 4), 15 hours (n = 2), 30
hours (n = 2) and 72 hours (n = 2) after injection of SPIO-labeled MSCs in both
kidneys. Signal intensity variations were correlated with the number of Prussian
blue stain-positive cells as visualized in histological specimens.
Results: In an in vivo study, it was determined that there was a significant dif-
ference in signal intensity variation for both the left and right cortex (40.8 ± 4.12
and 26.4 ± 7.92, respectively) and for both the left and right medulla (23.2 ±
3.32 and 15.2 ± 3.31, respectively) until two hours after injection (p < 0.05). In
addition, signal intensity variation in the left renal cortex was well correlated with
the number of Prussian blue stain-positive cells per high power field (r = 0.98, p <
0.05).
Conclusion: Intraarterial injected SPIO-labeled MSCs in an experimental rat
model of renal ischemia can be detected with the use of in vivo MR imaging
immediately after injection.
enal ischemia is the most common injury affecting renal tubular function
and is responsible for the majority of cases of acute renal failure in
hospital settings (1). This form of renal injury causes necrosis of both the
proximal tubule and the thick ascending limb, so called acute tubular necrosis (ATN)
(2). Following ischemic injury, tubular cells have been found to undergo necrosis,
apoptosis, detachment or dedifferentiation, and such dysfunction and loss of tubular
cells play a central role in the process underlying renal failure (1, 3). However, the
exact pathogenic mechanism of human renal ischemia is still unknown. In addition,
there are currently no therapeutic drugs approved by the United States Food and Drug
Administration (FDA) for the prevention or treatment of renal ischemic injury (1, 4).
In the past several years, extensive research has been focused on stem cell therapy
to create new functional components or to express tissue specific proteins in damaged
organs such as the heart, liver, brain, muscle and vascular endothelium (5-7). An
experimental study of stem cell therapy of renal disease has shown that adult bone
derived cells can contribute to renal remodeling (8). Furthermore, bone marrow
derived hematopoietic stem cells can also take part in the regeneration of the renal
tubular epithelium after ischemia-reperfusion as demonstrated in mice (9). Central to
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Rthe future success of these cell therapies is to evaluate the
ability of cells to migrate and engraft to target organs.
The use of magnetic resonance (MR) imaging would be
well suited to evaluate the ability of cells to migrate and
engraft to target organs, as MR imaging can provide a
detailed representation of target organs with excellent soft
tissue contrast and with the use of specialized contrast
agents. Paramagnetic or modified dextran-coated
superparamagnetic iron oxide (SPIO) contrast agents have
been used to label cells, allowing the researcher to monitor
cellular migration using MR imaging (10-13). However,
few studies have addressed the feasibility of the use of in
vivo MR imaging of cell therapies in models of renal
ischemia (14, 15). The aim of the present study is to assess
in vivo MR imaging with the use of a conventional 3-Tesla
MR imaging unit for the depiction of SPIO-labeled
mesenchymal stem cells (MSCs) in a rat model of renal
ischemia following intraarterial injection.
MATERIALS AND METHODS
Cell Culture and Labeling
Human MSCs (Bio-Whittaker, Walkersville, MD) were
grown in mesenchymal stem cell basal medium (MSCBM,
Bio-Whittaker) at 37℃ and in a 95% air, 5% CO2
atmosphere. Cells were maintained by replacement of the
growth media every four days. Human MSCs were co-
cultured in MSCBM containing FDA-approved SPIO
particles (Feridex; Berlex, Wayne, NJ). The iron concentra-
tions of the SPIO preparations were 25, 50, 100 and 
125 μ g/ml.
Poly-L-Lysine (PLL) (Sigma-Aldrich, St. Louis, MO) was
used as a transfection agent (TA). PLL coats the SPIO
through an electrostatic interaction and binds to the cell
membrane while inducing membrane bending;
subsequently, SPIO is endocytosed (16). PLL was mixed
with SPIO for 60 minutes in mesenchymal stem cell culture
medium at room temperature with the use of a rotating
shaker. The concentration of the TA was 0.75 μ g/ml for
each of the SPIO concentrations tested (10). After an
incubation period of three days, cells were washed twice
with phosphate buffered saline (PBS) to remove excess
contrast agent. For Prussian blue staining, cells were fixed
for 15 minutes with 4% paraformaldehyde, washed twice
with distilled water, and were incubated for 30 minutes
with a mixing solution of 0.5% potassium ferrocyanide
(Pearl’s reagent) and 0.5% HCl, after which the cells were
subsequently washed twice with PBS and counterstained
with eosin. Labeling efficiency was assessed by determina-
tion of the percentage of Prussian blue stain-positive cells
following labeling with SPIO at 25, 50, 100 and 125 μ g/ml.
The intracellular iron content was quantified after cell
labeling by the use of an iron-binding assay. Briefly, cells
were incubated with increasing concentrations of SPIO for
24 hours in the presence of PLL (0.75 μ g/ml). Cells were
then washed with culture medium and were then washed
three times with PBS, resuspended in 6 N HCl and were
incubated at 70℃ for 30 minutes. The iron content of
labeled cells was determined by use of a total iron reagent
set (Pointe Scientific, Canton, MI). With knowledge of the
iron content and the number of cells per sample, the
average iron content per cell was calculated (mean ±
standard deviation). The iron content of non-labeled cells
was also measured to obtain a control value.
The presence of SPIO particles was evaluated within
cells by the use of electron microscopy. Human MSCs
were fixed in a 1% dilution of 6% tannic acid and 25%
glutaraldehyde (Sigma-Aldrich). Fixed cells were
embedded on Thermanox plates (Nunc, Langenselbold,
Germany) and gelatin capsules filled with Epon, followed
by polymerization for 48 hours at 60℃. Electron
microscopy (JEM-100CX, JEOL, Tokyo, Japan) was
performed. Serial analysis was performed by using
magnifications ranging from ×4,400 to ×85,000. An
experienced board-certified pathologist performed visual
analysis with the use of electron microscopy.
Assessment of Viability and Proliferation
For assessment of toxicity and proliferation of SPIO-
labeled cells, human MSCs were evaluated with trypan
blue staining to verify membrane integrity. Cells were
labeled at SPIO concentrations of 25, 50, 100 and 
125 μ g/ml in 60 mm plates. After 1, 3 and 5 days, cells
were washed three times with PBS, trypsinized and were
collected in Eppendorf tubes. Cells were counted three
times with a hematocytometer to measure both viability
and proliferation.
Animal Models
All animal work was conducted in accordance with the
guidelines provided by the Institutional Animal Control
and Utilization Committee. For all manipulations, rats
were anesthetized with a 0.6-0.8 cc intramuscular injection
of 35-50 mg/kg ketamine hydrochloride (Yuhan
Yanghang, Seoul, Korea) and 5-10 mg/kg 2% xylazine
hydrochloride (Bayer Korea, Seoul, Korea).
Male Sprague-Dawley rats (n = 12) (weight range, 320-
400 g; age range, 10-13 weeks) were first anesthetized and
a 1.9 Fr microcatheter (Prowler-14, Cordis, Miami Lakes,
FL) was subsequently inserted into the mid common
carotid artery that had been previously exposed with a
paramedian incision of approximately 2 cm in the rat neck.
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renal artery for 40 minutes through the carotid artery and
thoracic aorta. Reflow was confirmed by the use of left
renal angiography with contrast media (3 cc; Pamiray,
Dongkook Pharmaceutical, Seoul, Korea) (Fig. 1). The
aforementioned procedure provided the rat models with
an ischemic and normal kidney on the left and right side,
respectively.
For injection preparation, human MSCs (Bio-Whittaker)
were labeled with 0.01% TA and 125 μ g/ml SPIO for 48
hours. Next, cells were washed three times with PBS,
trypsinized, washed twice after centrifugation at 300 ×g
for five minutes, and were counted. Cells were suspended
at 2 × 106/0.5 cc in PBS and were injected into both renal
arteries after selective renal angiography by the use of a
transcarotid approach. Rats were imaged immediately after
ischemia was induced prior to injection as a baseline image
(n = 2), and then two hours (n = 4), 15 hours (n = 2), 30
hours (n = 2) and 72 hours (n = 2) after the injection. Rats
were sacrificed immediately after MR imaging and both
kidneys were harvested for histological studies.
In order to compare the degree and extent of tubular
injury obtained with the method in the present study as
compared with the use of previously established models
using renal artery clamping, we evaluated tubular injury in
a histological specimen of a sacrificed ischemic kidney
using previously reported histological criteria after use of
the catheter lodging method (n = 2) and surgical clamping
(n = 2) (17). After we stained three axial sections of each
fixed kidney with Hematoxylin and Eosin, the degree of
tubular injury in random cortex and medulla fields was
scored with nine squares for each kidney with a high-
power field (HPF), and scores were compared for
specimens obtained by use of the catheter lodging method
and surgical clamping. A score for each tubular injury was
assigned as follows. Score 0 = normal histology; score 1 =
tubular cell swelling, with loss of the brush border, nuclear
condensation (apoptosis), up to one-third of the section
that showed nuclear loss (necrosis); score 2 = the same as
for score 1, except for greater than one-third and less than
two-thirds of nuclear loss per section; score 3 = greater
than two-thirds of the section showed nuclear loss
(necrosis).
MR Imaging
All MR imaging was performed with a 3-Tesla clinical
unit (Signa Excite; GE Healthcare, Milwaukee, WI) with an
8-channel head coil. T2* weighted gradient echo sequences
(repetition time msec/echo time msec, 400/15; flip angle,
15 ) were used to enhance the T2* effects of the SPIO
particles. The following image parameters were used: field
of view, 80×80 mm; matrix size, 256×160; section
thickness, 3 mm; number of excitation, 3; total acquisition
time, 3.40 minutes. Both kidneys were imaged in the axial
plane.
Changes in signal intensity (SI) were characterized by
use of region of interest (ROI) analysis on a well-centered
slice with an area of 1 mm
2. A minimum of 15 pixels was
required per region as displayed on a picture archiving and
communication system (PACS) workstation (Maroview;
Marotech, Seoul, Korea). The ROI was selected for the
renal cortex and medulla, and was placed to avoid suscep-
tibility effects arising from air-tissue interfaces in the
bowels. The value of the ROI was determined as the mean
± standard deviation after an estimated three times in the
upper pole, mid region and lower pole of each cortex or
medulla per one kidney, and was normalized to that of
back muscle (18, 19). SI changes in each rat were
calculated according to the use of the following formula:
(SI [pre] - SI [post])/SI (pre)×100; SI (pre) and SI (post)
are the normalized SI values as compared to back muscle
before and after labeled cell injection.
Histological Analysis
Rat kidney tissue blocks were fixed in 4% paraformalde-
hyde and were processed for paraffin embedding.
Microsections (4 μ m) were prepared with a microtome and
were used for Prussian blue staining to detect labeled iron
particles in the cells. An experienced board-certified
pathologist calculated the number of Prussian blue stain-
positive cells per HPF in each group. Prussian blue stain-
positive cells were counted in at least three HPFs per
section and a minimum of six sections of each kidney were
examined.
MRI of Magnetically Labeled Mesenchymal Stem Cells in Renal Ischemia Rabbit Model
Korean J Radiol 10(3), June 2009 279
Fig. 1. Left renal angiography after lodging in left renal artery with
microcatheter. Left renal angiography shows sluggish left renal
flow (arrow) after lodging for 40 minutes.Statistical Analysis
The Mann-Whitney test and Spearman’s rank correlation
were used to assess the variation between groups. A p
value < 0.05 was considered as statistically significant.
RESULTS
In Vitro Studies
For Prussian blue staining of human MSCs incubated
with varying concentrations of SPIO, numerous intracyto-
plasmic iron particles were observed in the MSCs with
Prussian blue staining. In cells incubated with 25, 50, 100
and 125 μ g/ml SPIO for one day, there were 97 ± 2.3, 97
± 2.7, 98 ± 0.5 and 99 ± 1.0 Prussian blue stain-positive
cells per 100 cells, respectively. There was no significant
difference among the labeled cells according to concentra-
tion of SPIO (p > 0.05). Electron microscopy demonstrated
that SPIO particles were present in endosomal vesicles
(Fig. 2).
The mean intracellular iron content at 25, 50, 100 and
125 μ g/ml SPIO was 257 ± 8.7, 240 ± 12.6, 322 ± 11.3
and 255 ± 5.5 pg/cell in comparison to 0.02 ± 0.04
pg/cell in the non-labeled control group. There was no
significant difference between the mean intracellular iron
content of labeled cells.
Five days after the initiation of SPIO labeling, no statisti-
cally significant decrease in the number of cells (p > 0.05)
or cell viability (p > 0.05) was observed for labeled and
control cells (non-labeled MSCs) at SPIO concentrations up
to 125 μ g/ml (Fig. 3).
In Vivo Animal Studies
Following intraarterial injection of labeled MSCs in both
the ischemic and control kidneys, a decrease in SI, which
was produced by susceptibility effects of SPIO, was
observed in the renal cortex and medulla on T2*-weighted
images (Fig. 4). The change in SI in the renal cortex and
medulla on T2*-weighted images peaked at two hours
after injection and subsequently declined (Fig. 5). Changes
in SI in the renal cortex between the ischemic and control
kidney were significantly different at two hours after
injection (40.8 ± 4.12 for the ischemic cortex and 26.4 ±
7.92 for the control cortex; p < 0.05) but was not signifi-
cantly different at 15, 30, and 72 hours after injection.
Similarly for the renal medulla, changes in SI between the
Jung et al.
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Fig. 3. Cell proliferation and viability of superparamagnetic iron oxide labeled mesenchymal stem cells. Any significant difference in
number of cells was not observed between control cells and superparamagnetic iron oxide labeled cells for concentrations up to 125 
μ g/ml for cell proliferation (A) and cell viability (B). Data are shown as means ± standard deviation.
AB
Fig. 2. Electron micrograph of superparamagnetic iron oxide
labeled mesenchymal stem cells (original magnification, ×4,800).
There are multiple endosomal vesicles containing superparamag-
netic iron oxide particles (arrows) seen in cytoplasm of
mesenchymal stem cells.ischemic and control kidney were significantly different at
two hours after injection (23.2 ± 3.32 for the ischemic
medulla and 15.2 ± 3.31 for the control medulla; p <
0.05) but not at any time thereafter.
Prussian blue staining was used to identify SPIO particles
in the ischemic and control kidney (Fig. 6). The number of
Prussian blue stain-positive cells per HPF in the renal
cortex and medulla of the ischemic kidney peaked at two
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AB
CD
Fig. 4. T2*-weighted MR images before (A), 2 hours (B), 15 hours
(C), 30 hours (D) and 72 hours (E) after injection of labeled
mesenchymal stem cells. Left Ischemic kidney shows distinct
decreased signal intensity (arrows) in cortex (B). However, signal
intensity decrease shows progressive fading in C (arrows), D and
E.
Ehours after injection and subsequently declined (Fig. 7).
There were significantly more Prussian blue stain-positive
particles per HPF in the cortex and medulla ischemic
kidneys than in the control kidneys. The number of
Prussian blue stain-positive particles per HPF peaked at
two hours after injection (25.7 ± 5.31 for the ischemic
cortex and 11.2 ± 7.36 for the control cortex; p < 0.05;
6.7 ± 3.13 for the ischemic medulla and 2.2 ± 1.17 for
the control medulla; p < 0.05). The number of Prussian
blue stain-positive cells per HPF in the cortex of the
ischemic kidney was positively correlated with a decrease
in SI (r = 0.98, p < 0.05). However, the number of Prussian
blue stain-positive cells per HPF in the medulla of ischemic
kidney was not significantly correlated with a decrease in
SI (r = 0.94, p > 0.05).
For the comparison between specimens obtained with
use of the catheter lodging method and specimens obtained
with use of surgical clamping, we did not find any signifi-
cant differences with respect to the score of injury between
the use of the catheter lodging method (2.1 ± 0.68) and
surgical clamping (2.3 ± 0.84) (p > 0.05).
DISCUSSION
The results of our study have demonstrated that human
MSCs could be successfully labeled in vitro with commer-
cially available SPIO particles and a transfection agent.
Moreover, we have demonstrated that due to the suscepti-
bility effect, SPIO labeled MSCs could be detected in vivo
by the use of a clinically available 3-Tesla MR unit after
intraarterial injection in a rat model of renal ischemia.
Results obtained with the use of in vitro labeled human
MSCs in our study generally agreed with findings of
previous studies that have demonstrated the usefulness of
iron oxide particles to label MSCs (10, 20, 21). It is
important that labeled MSCs maintain the ability to differ-
entiate in a given concentration of SPIO, as labeled MSCs
used in cell therapy are expected to differentiate in order
to regenerate damaged tissues. Therefore, conservation of
Jung et al.
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Fig. 7. Time course of number of Prussian blue staining-positive
cells per high-power field. Graph shows number of Prussian blue
stain-positive cells in renal cortex and medulla after labeled
mesenchymal stem cells injection as function of time. At two
hours after injection, sharp decrease in number of cells is
observed in renal cortex and medulla of ischemic kidney (LT).
Gradual decrease in number of particles is observed in renal
cortex and medulla of control kidney (RT). Data are shown as
means ± standard deviation.
Fig. 5. Time course of signal intensity decrease on T2*-weighted
image. 
Graph shows that signal intensity change on T2*-weighted image
in renal cortex and medulla decreases with time after injection of
labeled mesenchymal stem cells. Difference for signal intensity
change was prominent at two hours in renal cortex and medulla
for ischemic kidney (LT) and control kidney (RT). Data are shown
as means ± standard deviation.
Fig. 6. Micrograph of histological specimen of ischemic kidney
obtained at two hours after superparamagnetic iron oxide labeled
mesenchymal stem cells injection (original magnification, ×200).
Arrows indicate Prussian blue stain-positive particles in glomeruli
and tubules of renal cortex.viability and proliferation following SPIO labeling is
essential. Our results indicate that there was no significant
difference in cell viability and proliferation between
control cells and cells labeled with up to 125 μ g/ml SPIO;
this concentration of SPIO was determined to exhibit the
highest SI change for cells in an in vivo study. 
The rat ischemic model was based on the use of the
catheter lodging method in the renal artery for 40 minutes
with a transcarotid approach. We chose this method
primarily as it is a less invasive technique than the use of
renal artery clamping after transperitoneal incision, which
results in a reduction of experimental animal mortality. In
addition, the technique is a more sophisticated method to
confirm the presence of reflow and spasm of the renal
artery of the ischemic kidney. There were no significant
differences between the use of the catheter lodging method
and the surgical clamping method with respect to the
extent of injury with more than a score of 1. However, we
have speculated that the catheter lodging method could not
produce global high-grade tubular injury more frequently
than the surgical clamping method due to the difficulty of
causing a tight occlusion.
In most reports that have described MR imaging of
magnetically labeled MSCs, local implantation has been
used as the route for cell grafting into the rat brain and
spinal cord (22, 23). Such an invasive approach is not
suitable for the kidney, where damaged components often
have a widespread distribution, and stereotactic methods
cannot be applied due to the influence of respiratory
motion. Thus, we used an intraarterial route for cell
grafting, as a large number of cells could be directly
delivered to the target organ.
The histological data obtained in the present study
showed that Prussian blue stain-positive cells were found
mainly within the renal cortex of the ischemic kidney at
two hours after injection. This finding may be due to cells
that were mechanically trapped in the damaged glomerular
tuft or was due to active recruitment to the acute injury
site. However, it was likely that mechanical trapping was
the dominant factor based on the immediate presence of
Prussian blue stain-positive cells and rapid fading in the
renal cortex from 15 hours after injection. Regardless of
whether the predominant presence of Prussian blue stain-
positive cells in the ischemic cortex was due to passive
effects or local trophic effects, a decrease in the number of
Prussian blue stain-positive cells was observed in the
ischemic renal cortex. In addition, the decrease in the
number of stained cells was well correlated with a change
in SI as seen on a T2*-weighted MR image. Eventually, the
difference in SI between the ischemic and normal cortex
was not significant at 15, 30 and 72 hours after injection.
This finding suggested that the SPIO labeled cells were
predominantly detected only in the ischemic cortex
immediately after injection; thereafter, only a small
number of SPIO labeled cells were retained in both the
ischemic and normal cortex, presumably by the same
mechanism.
In the ischemic renal medulla, we did observe a gradual
decrease in the number of Prussian blue stain-positive cells;
however, this pattern was not significantly correlated with
a change in SI as seen on a T2*-weighted MR image. The
lack of correlation may have been due to a small number
of samples that were insufficient for statistical significance,
or was due to the presence of a tubular cast containing
hemoglobin or hemorrhage that usually occurs in the
medulla of ischemic ATN, which caused a confounding
susceptibility effect as seen on a T2*-weighted MR image.
There are some limitations to this study. First, we used
only commercially available human MSCs, and not rat
MSCs, to facilitate an in vitro process as we focused on the
validity of MR imaging for the depiction of SPIO-labeled
MSCs in renal ischemia rather than to assess recovery of
renal function. Second, we did not perform immunohisto-
chemical analysis on human MSCs under the conditions
that we tested with the rat model, and therefore could not
confirm whether Prussian blue stained positive particles
were associated with labeled SPIO in MSCs in vivo. Third,
the number of animals in this study was not sufficient to
reproduce and statistically analyze the current results.
Fourth, a study evaluating cell trafficking through
intravenous injection, for example, with MR imaging of the
spleen, bone marrow and liver, should be conducted to
identify the mechanism of targeted cellular homing to
damaged components. Finally, we did not perform an
intraindividual longitudinal comparison of MR SI variation
in rats due to the relatively short survival period after such
procedures as catheter lodging and the use of frequent MR
scanning.
In conclusion, intraarterial injected SPIO-labeled MSCs
in renal ischemia induced in the rat can be depicted with
the use of in vivo MR imaging immediately after injection.
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